BioCentury | Sep 20, 2020
Product Development

Amgen highlights durability, seeks biomarkers as response rates slip for KRAS inhibitor AMG 510

...commonly mutated oncogenes such as ALK and EGFR...
...tumor types. TARGETSALK – Anaplastic lymphoma kinaseEGFR (ErbB1; HER1...
BioCentury | Sep 19, 2020
Product Development

Sept. 18 ESMO roundup: data from Incyte, Autolus, Merck, Alkermes and Daiichi

...fusion protein of circularly permuted IL-2 and CD25. Daiichi planning Phase II for ADC in EGFR-mutated...
...U3-1402) showing the antibody-drug conjugate targeting HER3 led an ORR of 25% among patients with EGFR-mutated...
BioCentury | Sep 18, 2020
Management Tracks

Former AZ CMO Bohen brings his cancer chops to Olema

...Lynparza olaparib, and Tagrisso osimertinib, an oral irreversible inhibitor of EGFR-activating mutations and the T790M EGFR...
...Epidermal growth factor receptor 2 Danielle Golovin OP-1250 Tagrisso (Brand), AZD9291 (Compound #), osimertinib (Generic), Tagrisso (Other) Faslodex, fulvestrant (ICI 182,780) AstraZeneca plc Olema Oncology Epidermal growth factor receptor...
BioCentury | Sep 16, 2020
Management Tracks

HHS follows FDA, replacing political communications leader with career staff

Following public disclosures that he had promoted conspiracy theories and accused CDC staff of plotting sedition, HHS announced Wednesday that its assistant secretary for public affairs, Michael Caputo, was taking a 60-day leave of absence...
BioCentury | Sep 15, 2020
Deals

With $1.7B in Merck deals, Seattle Genetics plots broader pipeline

...$171.79 on Monday. TARGETSHER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor...
BioCentury | Sep 15, 2020
Product Development

Data Bytes: Trodelvy leads TROP2 pack

Five therapies in the TROP2 pipeline together address at least seven types of cancer plus undisclosed solid tumors. The most advanced, Trodelvy sacituzumab govitecan-hziy, is the centerpiece of the $21 billion acquisition of Immunomedics Inc. by...
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...98%) to $83.65.TARGETSHER2 (EGFR2; ErbB2; neu) - Epidermal growth factor receptor...
BioCentury | Sep 10, 2020
Product Development

Medicxi’s de Rubertis hopes for positive future for infectious disease after COVID-19: a BioCentury audio interview

Francesco de Rubertis, co-founder and partner of Medicxi, is optimistic that the COVID-19 pandemic might lead to an increased interest in infectious disease investment, but it will take government action to create the incentives. de...
BioCentury | Sep 10, 2020
Product Development

Qiming’s Leung: COVID-19 response displays the deep networks of China’s biotech ecosystem: a BioCentury audio interview

The picture Nisa Leung, managing director of Qiming Venture Partners, paints of the response among Chinese biotechs to COVID-19 is one that underscores how the local ecosystem has matured from a “budding...
BioCentury | Sep 9, 2020
Product Development

McMurry-Heath: COVID-19 raises stakes for industry to take the lead on promoting science: a BioCentury audio interview

Michelle McMurry-Heath, three months into her role as president and CEO of BIO, sees the pandemic as a crucial time for the biopharma industry to tell its story better to the public, and ensure its...
Items per page:
1 - 10 of 6903